EverythingALS, the patient-focused nonprofit leveraging technology and data science to accelerate care and research for ALS, today announced the launch of SAVA, an AI-powered clinical trial matching tool that connects ALS patients with clinical trials they may qualify for.
Historically, many patients are unaware of ongoing clinical trials, or their physicians may not know about every available opportunity. SAVA AI changes that by using citizen-driven research and data-driven insights to directly empower patients. Available on the EverythingALS website and free app, patients now can securely provide their data, receive real-time alerts about relevant clinical trials they are eligible for, and share this information with their physicians and family members. The collective data is made available to researchers and pharmaceutical companies, strengthening the entire ALS ecosystem.
“We created SAVA AI because access to clinical trials should never depend on chance, geography, or connections,” said Indu Navar, Founder of EverythingALS. “By harnessing AI and citizen-driven research, we’re giving patients the power to find opportunities that could change the course of their own disease journey, and accelerating the entire community’s path toward a cure.”
We named our AI, SAVA, after our dear friend living with ALS in Amsterdam, and he reflects EverythingALS’s mission of moving from “Care to Cure.” By democratizing access to information, SAVA AI ensures that clinical trial opportunities no longer depend on geography or connections but instead on personalized AI matching. Patients can also be guided toward genetic testing and other treatments that are critical to advancing research.
SAVA AI is powered by multiple collaborating AI agents within the EverythingALS platform. One AI tracks patient health data, while another identifies and matches patients to the most relevant clinical trials. These Agentic AI systems use only EverythingALS synthesized data and insights, ensuring security, privacy and accuracy while serving the ALS community.
The EverythingALS app is available for free nationwide. Patients, caregivers, and healthy individuals are encouraged to download the app, look up trials and participate in ongoing research.
For more information and to download the app, visit: https://www.everythingals.org
About EverythingALS
EverythingALS has been dedicated to advancing ALS research, fostering innovation, and offering support for individuals and families affected by ALS. EverythingALS is a non-profit 501(c)(3) organization that operates under the Peter Cohen Foundation. EverythingALS has established a well-connected ALS community network comprising 7,000 subscribers, 1,400 research participants, and over 300,000 visitors to its YouTube channel from over 60 countries. Furthermore, EverythingALS collaborates with neurologists and scientists from Harvard, MGH, Temple University, MIT and a consortium of 22 pharmaceutical companies, sharing research findings and insights through its unique citizen-driven research with an open innovation model to bring cures. With a strong emphasis on collaboration and data-driven approaches, EverythingALS is committed to accelerating the development of curative therapies for ALS, aiming for a world free from the burdens of ALS. http://www.everythingals.org and http://v2030.org
View source version on businesswire.com: https://www.businesswire.com/news/home/20260429743914/en/
Media gallery
